You just read:

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia

News provided by

Celator Pharmaceuticals, Inc.

14 Jun, 2016, 07:00 ET